Patents Assigned to Ablynx N.V.
  • Amino acid sequences directed against chemokines and polypeptides comprising the same for the treatment of chemokine-related diseases and disorders
    Patent number: 8906680
    Abstract: The present invention relates to amino acid sequences that are directed against chemokines, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: December 9, 2014
    Assignee: Ablynx N.V.
    Inventors: Christophe Blanchetot, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard
  • Polypeptides that modulate the interaction between cells of the immune system
    Patent number: 8907065
    Abstract: The present invention relates to amino acid sequences that block the interaction between (a target on) an antigen presenting cell (APC) and (a target on) a T-cell. More particularly, the present invention relates to amino acid sequences that are directed against (as defined herein) a target on an APC (also referred to herein as “APC target”) or a target on a T-cell (also referred to herein as “T-cell target”). The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: December 17, 2007
    Date of Patent: December 9, 2014
    Assignee: Ablynx N.V.
    Inventors: Guy Hermans, Peter Verheesen, Edward Dolk, Hendricus Renerus Jacobus Mattheus Hoogenboom, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Renee de Bruin
  • INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20140349342
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Application
    Filed: April 23, 2014
    Publication date: November 27, 2014
    Applicant: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20140348830
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Application
    Filed: April 23, 2014
    Publication date: November 27, 2014
    Applicant: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS
    Publication number: 20140343257
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: March 21, 2014
    Publication date: November 20, 2014
    Applicant: ABLYNX N.V.
    Inventors: ELS ANNA ALICE BEIRNAERT, CEDRIC JOZEF NEOTERE VERVERKEN, JOOST ALEXANDER KOLKMAN, MAARTEN VAN ROY
  • BIOLOGICAL MATERIALS RELATED TO C-MET
    Publication number: 20140341903
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Application
    Filed: October 1, 2012
    Publication date: November 20, 2014
    Applicant: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA
    Publication number: 20140335101
    Abstract: The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: February 27, 2014
    Publication date: November 13, 2014
    Applicant: Ablynx N.V.
    Inventor: Els Anna Alice Beirnaert
  • AMINO ACID SEQUENCES DIRECTED AGAINST IL-6R AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF IL-6R RELATED DISEASES AND DISORDERS
    Publication number: 20140329278
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Application
    Filed: March 21, 2014
    Publication date: November 6, 2014
    Applicant: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy
  • Amino acid sequences directed against the Angiopoietin/Tie system and polypeptides comprising the same for the treatment of diseases and disorders related to angiogenesis
    Patent number: 8858940
    Abstract: The present invention relates to amino acid sequences that are directed against proteins from the group of the Angiopoietin/Tie family such as Tie1, Tie2, Ang1, Ang2, Ang3, Ang4, Angptl1, Angptl12, Angptl13, Angptl14, Angptl15, Angptl16, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more of such amino acid sequences.
    Type: Grant
    Filed: December 10, 2009
    Date of Patent: October 14, 2014
    Assignee: Ablynx N.V.
    Inventors: Maria Gonzalez Pajuelo, Michael John Scott Saunders, Johannes Joseph Wilhelmus De Haard, Peter Vanlandschoot
  • BIOLOGICAL MATERIALS RELATED TO C-MET
    Publication number: 20140294847
    Abstract: The present invention relates to biological materials related to c-Met possibly in combination with VEGF and/or EGFR, and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. Methods and kits for assessing the responsiveness of a patient to c-Met therapy are also described and provided.
    Type: Application
    Filed: March 5, 2014
    Publication date: October 2, 2014
    Applicant: Ablynx N.V.
    Inventors: Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Cedric Jozef Neotere Ververken, Tinneke Denayer
  • SERUM ALBUMIN BINDING PROTEINS
    Publication number: 20140228546
    Abstract: The present invention relates to amino acid sequences that are capable of binding to serum albumin; to proteins and polypeptides comprising or essentially consisting of such amino acid sequences; to nucleic acids that encode such amino acid sequences, proteins or polypeptides; to compositions, and in particular pharmaceutical compositions, that comprise such amino acid sequences, proteins and polypeptides; and to uses of such amino acid sequences, proteins and polypeptides.
    Type: Application
    Filed: June 14, 2012
    Publication date: August 14, 2014
    Applicant: Ablynx N.V.
    Inventors: Bruno Dombrecht, Peter Schotte, Cedric Josef Neotere Ververken
  • INTERLEUKIN-6 RECEPTOR BINDING POLYPEPTIDES
    Publication number: 20140221623
    Abstract: The invention relates to amino acid sequences that are directed against and/or that can specifically bind to IL-6 receptor, compounds or constructs that comprise said amino acid sequence, nucleic acids that encode said amino acid sequences, compounds or constructs, pharmaceutical compositions comprising said amino acid sequences, compounds or constructs as well as methods for the prevention and/or treatment of diseases and disorders associated with IL-6 receptor.
    Type: Application
    Filed: December 30, 2013
    Publication date: August 7, 2014
    Applicant: Ablynx N.V.
    Inventors: Joost Alexander Kolkman, Els Anna Alice Beirnaert
  • PROLONGED INHIBITION OF INTERLEUKIN-6 MEDIATED SIGNALING
    Publication number: 20140212417
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: September 24, 2012
    Publication date: July 31, 2014
    Applicant: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Özkan Yalkinoglu
  • AMINO ACID SEQUENCES DIRECTED AGAINST RANK-L AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF BONE DISEASES AND DISORDERS
    Publication number: 20140205601
    Abstract: The present invention relates to amino acid sequences that are directed against RANK-L, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences. The invention also relates to nucleic acids encoding such amino acid sequences and polypeptides; to methods for preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes.
    Type: Application
    Filed: December 11, 2013
    Publication date: July 24, 2014
    Applicant: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Sigrid Cornelis, Hendricus Renerus Jacobus Mattheus Hoogenboom
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20140205597
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: December 23, 2013
    Publication date: July 24, 2014
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens, Bruno Dombrecht, Peter Schotte, Cedric Jozef Neotere Ververken, Gerald Beste, Guy Hermans, Soren Steffensen, Alexander Szyroki, Tinneke Denayer
  • TECHNIQUES FOR PREDICTING, DETECTING AND REDUCING ASPECIFIC PROTEIN INTERFERENCE IN ASSAYS INVOLVING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS
    Publication number: 20140199295
    Abstract: This invention provides, and in certain specific but non-limiting aspects relates to: assays that can be used to predict whether a given ISV will be subject to protein interference as described herein and/or give rise to an (aspecific) signal in such an assay (such as for example in an ADA immunoassay).
    Type: Application
    Filed: June 25, 2012
    Publication date: July 17, 2014
    Applicant: Ablynx N.V.
    Inventors: Judith Baumeister, Marie-Paule Lucienne Armanda Bouche, Carlo Boutton, Marie-Ange Buyse, Veerle Snoeck, Stephanie Staelens
  • BIOLOGICAL MATERIALS RELATED TO CXCR7
    Publication number: 20140178390
    Abstract: The present invention relates to particular polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the present invention provides immunoglobulin single variable domains inhibiting CXCR7 mediated tumour growth.
    Type: Application
    Filed: July 9, 2013
    Publication date: June 26, 2014
    Applicant: Ablynx N.V.
    Inventors: Francis Descamps, David Andre Baptiste Maussang-Detaille, Maarten Van Roy, Maria Gonzalez Pajuelo, Regorius Leurs, Pascal Gerard Merchiers, Martine Smit, Catelijne Stortelers, Philippe Van Rompaey, Peter Vanlandschoot
  • STABLE FORMULATIONS OF POLYPEPTIDES AND USES THEREOF
    Publication number: 20140178383
    Abstract: Formulations are provided that contain single variable domains with a good solubility and good stability under different storage, transportation and stress conditions. The formulations are useful as pharmaceutical formulation. The formulation comprises an aqueous carrier with a pH of 5.5 to 8.0, a buffer selected from the group consisting of histidine pH 6.0-6.5, hepes pH 7.0-8.0, MES pH 6.0, succinate pH 6.0-6.5 and acetate pH 5.5-6.0; an excipient; and/or a surfactant selected from Tween 80, Tween 20 and poloxamers. The formulation is further characterized that it has an inorganic salt concentration of 150 mM or lower. The invention further relates to containers and pharmaceutical units comprising such formulations and to methods for preparing and prophylactic and therapeutic uses of the formulations and pharmaceutical units of the invention.
    Type: Application
    Filed: August 12, 2013
    Publication date: June 26, 2014
    Applicant: Ablynx N.V.
    Inventors: Ann Brige, Christine Labeur, Veronique De Brabandere, Marc Lauwereys
  • Inhibition of Bone Resorption with Rankl Binding Peptides
    Publication number: 20140170167
    Abstract: Methods are provided for inhibiting bone resorption and/or osteoclast activity. More specifically, methods are provided wherein polypeptides against RANK-L are administered to a subject less frequently and/or at lower dose, while still maintaining effective inhibition of bone resorption and/or osteoclast activity in the subject at unexpectedly prolonged periods of time, particularly in view of the doses administered.
    Type: Application
    Filed: May 29, 2012
    Publication date: June 19, 2014
    Applicant: Ablynx N.V.
    Inventors: Josefin-Beate Holz, Alex Hemeryck
  • Anti-IL-6R polypeptides and pharmaceutical compositions thereof
    Patent number: 8748581
    Abstract: The present invention relates to amino acid sequences that are directed against/and or that can specifically bind Interleukin-6 Receptor (IL-6R) with improved affinity and/or avidity, and/or that have an improved efficacy and/or potency, and which are capable of (partially, or preferably totally) blocking the IL-6/IL-6R interaction and/or inhibit signalization through IL-6, IL-6R and/or the IL-6/IL-6R complex. The invention further relates to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: June 10, 2014
    Assignee: Ablynx N.V.
    Inventors: Els Anna Alice Beirnaert, Cedric Jozef Neotere Ververken, Joost Alexander Kolkman, Maarten Van Roy